{"url":"https://newsforagent.com/news/2026-11-04/revmedica-mike-jones-chief-executive","markdown_url":"https://newsforagent.com/news/2026-11-04/revmedica-mike-jones-chief-executive.md","title":"RevMedica Names Mike Jones CEO as Stapler Nears Market","headline":"RevMedica Appoints Former Boston Scientific Endoscopy Head Mike Jones as CEO","description":"RevMedica named Mike Jones, former head of Boston Scientific's $3 billion Endoscopy unit, as CEO, succeeding founder Tom Wenchell, now President and COO.","section":"Leadership","published_at":"2026-11-04T16:18:35+00:00","modified_at":"2026-11-04T16:18:35+00:00","author":"News Desk","key_takeaways":["Mike Jones, former president of Boston Scientific's approximately $3 billion Endoscopy division, became RevMedica's CEO and a board member.","Founder Tom Wenchell moved from CEO to President and Chief Operating Officer, retaining product development and technical operations.","RevMedica's powered surgical stapling platform is advancing toward limited market release and is not cleared for commercial sale in the United States."],"companies":[{"name":"Revmedica","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0002oyi/revmedica","website":"https://www.revmedica.com"}],"source":{"publisher":"PR Newswire","title":"RevMedica Appoints Former Boston Scientific Executive Mike Jones as Chief Executive Officer","url":"https://www.prnewswire.com/news-releases/revmedica-appoints-former-boston-scientific-executive-mike-jones-as-chief-executive-officer-302928355.html"},"other_sources":[],"tags":["Leadership","Revmedica"],"body_markdown":"RevMedica appointed Mike Jones, former president of Boston Scientific's approximately $3 billion Endoscopy division, as chief executive officer and a board member, the company said in a [PR Newswire](https://www.prnewswire.com/news-releases/revmedica-appoints-former-boston-scientific-executive-mike-jones-as-chief-executive-officer-302928355.html) announcement on November 4, 2026. Jones succeeds founder Tom Wenchell, who becomes president and chief operating officer.\n\n## Jones Takes Over as Wenchell Moves to Operations\n\nJones spent more than 30 years in global MedTech leadership and most recently served as senior vice president and president of Boston Scientific's Endoscopy division. In that role he oversaw research and development, commercial execution, manufacturing and strategic business development across global operations.\n\nAt [RevMedica](https://akta.pro/company-profiles/0002oyi/revmedica), Jones will lead strategic direction as the company advances regulatory and clinical milestones, prepares for limited market release and builds a commercialization strategy. \"RevMedica represents a compelling opportunity to bring meaningful innovation to a critical area of surgery,\" Jones said in the announcement.\n\nWenchell will continue to lead engineering, product development, technical operations and day-to-day business execution. \"Mike brings an exceptional combination of commercial leadership, strategic vision, and a proven ability to build and scale successful medical technology businesses,\" Wenchell said.\n\nRevMedica's powered surgical stapling platform combines real-time tissue sensing and feedback intended to give surgeons data on tissue characteristics during stapling. The company holds more than 30 issued US patents, according to the announcement, and its products are not currently cleared for commercial sale in the United States.\n\n## RevMedica's Funding and Patent Record\n\nRevMedica's [funding records](https://akta.pro/company-data) on akta.pro list three rounds, including a $14.2 million round in June 2023, a $275,881 National Science Foundation grant in April 2021 and non-equity assistance in May 2019. The same records show total funding of $14.4 million and a headcount range of 11 to 50.\n\nCompany records also list a $14.2 million exempt securities offering under Rule 506(b) involving 41 investors. The records describe RevMedica as a pre-commercial company founded in 2017 and based in Middletown, Connecticut, awaiting FDA clearance for its Endo Stapling Platform.\n\n## FDA Program and Clinical Presentation Ahead\n\nRevMedica's Endo Stapling Platform was accepted into the FDA's Safer Technologies Program in January 2025, according to akta.pro company records. The same records state that an abstract on its real-time intraoperative insight technology was accepted for presentation at the SAGES 2026 Annual Meeting.\n\nThe company's platform received the FDA Safer Technologies designation in October 2024, the announcement said. RevMedica's website is [revmedica.com](https://www.revmedica.com).\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}